Effects of chemically modified tetracycline, CMT-8, on bone loss and osteoclast structure and function in osteoporotic states.
We examined the effects of a nonantimicrobial tetracycline analogue, CMT-8, on bone loss and osteoclasts in ovariectomized (OVX) rats. Three-month-old female rats were OVX, and, one week later, distributed into three groups: sham-operated non-OVX controls, untreated OVX controls, and CMT-8-treated OVX rats. After 145 days of daily drug administration (p.o.), the femurs were dissected and examined histologically. Ovariectomy markedly decreased trabecular and cortical bone volume in the metaphyses compared to sham-operated controls. Treating the OVX rats with CMT-8 produced a significant inhibition of trabecular and cortical bone loss and induced new bone formation, in which connectivity of the trabecular struts was increased by bridging the adjacent longitudinal bone trabeculae. Ultrastructurally, CMT-8 reduced ruffled border formation in osteoclasts, while it caused no structural impairment in osteoblasts. To further evaluate the effects of CMT-8 on the resorbing activity of osteoclasts, osteoclasts were cultured on dentine slices pretreated with CMT-8 at concentrations of 2, 10, or 50 micrograms/ml, and resorption lacuna formation on the dentine surface was found to be reduced, dose-dependently, by the bound CMT-8. Our results suggest that CMT-8 therapy effectively inhibits post-ovariectomy bone loss not only by inducing new bone formation, but also by inhibiting osteoclastic bone resorption, and that CMT-8 binding to bone may provide a prolonged release delivery of this anti-resorptive therapy.
Sasaki
T
T
Department of Anatomy and Cell Biology, Showa University Dental School, Tokyo, Japan.
Ohyori
N
N
Debari
K
K
Ramamurthy
N S
NS
Golub
L M
LM
D000818:Animals; D001842:Bone and Bones / Q000166:cytology / Q000187:drug effects* / Q000473:pathology; D002478:Cells, Cultured; D005260:Female; D005269:Femur / Q000166:cytology / Q000187:drug effects / Q000473:pathology; D006811:Humerus / Q000166:cytology / Q000187:drug effects / Q000473:pathology; D051379:Mice; D008815:Mice, Inbred Strains; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects* / Q000648:ultrastructure; D010024:Osteoporosis / Q000517:prevention & control*; D010052:Ovariectomy; D011480:Protease Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D013754:Tetracyclines / Q000494:pharmacology* / Q000627:therapeutic use
D011480:Protease Inhibitors; D013754:Tetracyclines; C117153:tetracycline CMT-8